World Library  
Flag as Inappropriate
Email this Article

Ubenimex

Article Id: WHEBN0025360938
Reproduction Date:

Title: Ubenimex  
Author: World Heritage Encyclopedia
Language: English
Subject: Arachidonic acid 5-hydroperoxide, Protease inhibitors, Kobret, 6β-Naltrexol-d4, Hemorphin
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Ubenimex

Ubenimex[1]
Identifiers
CAS number ,  (HCl)
PubChem
ChemSpider
ChEMBL  YesY
Jmol-3D images Image 1
Properties
Molecular formula C16H24N2O4
Molar mass 308.37 g mol−1
Melting point 245 °C (473 °F) (dec.)
Hazards
S-phrases S22 S24/25
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY   YesY/N?)

Ubenimex (INN), also known by the brand name bestatin, is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B,[2] leukotriene A4 hydrolase,[3] and aminopeptidase N.[4] It is being studied for use in the treatment of acute myelocytic leukemia.[5] It is derived from Streptomyces olivoreticuli.[6]

Crystal structure of ubenimex
Crystal structure of ubenimex in the binding pocket of leukotriene A4 hydrolase. Rendered from PDB 1HS6.

References

  1. ^ N-((2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl)-L-leucine at Sigma-Aldrich
  2. ^ Umezawa,H., Aoyagi,T., Suda,H., Hamada,M. & Takeuchi,T. (1976). "Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes." (29). pp. 97–99. 
  3. ^ Muskardin,D.T., Voelkel,N.F. & Fitzpatrick,F.A. (1994). "Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase." (48). pp. 131–137. 
  4. ^ K Sekine, H Fujii and F Abe (1999). "Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines" 13 (5). pp. 729–734. 
  5. ^ Hirayama, Y; Sakamaki, S; Takayanagi, N; Tsuji, Y; Sagawa, T; Chiba, H; Matsunaga, T; Niitsu, Y (2003). "Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival". Gan to kagaku ryoho. Cancer & chemotherapy 30 (8): 1113–8.  
  6. ^ Bauvois, B; Dauzonne, D (January 2006). "Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospects". Medicinal Research Reviews 26 (1): 88–130.  

External links

  • The MEROPS online database for peptidases and their inhibitors: Bestatin



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.